ValueJune 22, 2026

Buy the Dip Monday: 66% ROIC at an 87% Discount and $16M in Insider Commitments

Top 5 Pixie Picks

This Week's Setup

The screen surfaces eight names trading below ten-year average multiples while generating double-digit earnings yields, a setup that narrows sharply when the S&P 500 CAPE remains pinned at 38.9.

Fear & Greed at 36 marks a shift from the neutral zone into cautious positioning, yet three tickers show ROIC above 24% and insider purchases totaling over $16 million in the past six months.

The valuation floor appears distinct from recent weeks: semiconductor capital equipment and gold miners now sit alongside pharma names with gross margins above 78%, each offering a different path through a compressed macro landscape.

Quick Scan

#	Ticker	One-line thesis
1	AEO	Retail turnaround with 7.5% ROIC and 38% drawdown
2	EQT	Natural gas volume surge with insider buying
3	GDX	Gold miner basket down 31% from peak
4	GILD	Pharma ROIC leader with FDA approval momentum
5	GSK	Diversified pharma with first-in-class antibiotic launch
6	KLAC	Semiconductor toolmaker with 66% ROIC, 87% drawdown
7	NEM	Gold producer with 30% ROIC, block cave approval
8	REGN	Ophthalmology leader with $403K insider net buys

The 8 Names

1. American Eagle Outfitters, Inc. (AEO)

P/E: 11.1 | Earnings yield: 9.0% | 52w drawdown: -38.2%

The retailer delivers a 6.6% FCF yield against a 2.8% dividend, creating a 2.3× payout cover while revenue growth holds at 4.1% year-over-year. Normalized P/E sits at 16.5, placing the current 11.1 multiple below the ten-year average despite sustained gross margins of 36.5%.

Insiders have been net sellers over the past six months, unloading 1.06 million shares with zero offsetting purchases. Short interest stands at 8.8% of float, the highest concentration on this screen.

The analyst target of $19.67 implies 11.9% upside, but the stock has generated only 0.17% annualized price appreciation over the past year, suggesting investors remain unconvinced by the Q1 beat.

2. EQT Corporation (EQT)

P/E: 9.6 | Earnings yield: 10.4% | 52w drawdown: -25.8%

Revenue climbed 60% year-over-year while ROIC reached 9.2%, driving a 9.0% FCF yield that more than doubles the 1.3% dividend. EV/EBITDA of 5.7 and debt-to-equity of 0.25 position the balance sheet for continued distribution capacity expansion.

CEO Toby Z. Rice added shares on June 9, part of a broader six-month pattern in which insiders purchased 583,874 net shares at an aggregate cost of $5.66 million. The insider buy-to-sell ratio stands at 15.1% buy versus 2.1% sell.

Analyst consensus targets $70.04, implying 38.2% upside, yet the stock's one-year trend is flat at 0.04% annualized, flagging a disconnect between fundamental trajectory and market conviction.

3. VanEck Gold Miners ETF (GDX)

P/E: 17.0 | Earnings yield: 5.9% | 52w drawdown: -31.3%

The ETF consolidates exposure to producers now trading at a 31.3% drawdown from their 52-week peak while the ten-year earnings yield sits at 1.4%, compressing the relative value opportunity into a narrow band of names with near-term production visibility.

The 17.0 P/E reflects a basket weighted toward development-stage assets and jurisdictional risk profiles that elevate multiples relative to established majors, creating dispersion within the constituent universe.

Gold equities have historically lagged spot price recoveries by several quarters, meaning interim volatility can persist even if bullion stabilizes.

4. Gilead Sciences, Inc. (GILD)

P/E: 16.9 | Earnings yield: 5.9% | 52w drawdown: -21.2%

ROIC of 24.4% leads the screen while gross margin holds at 78.8%, generating a 6.1% FCF yield that supports a 2.6% dividend and ongoing share repurchases. Revenue grew 2.4% year-over-year, stabilizing the base business as HIV and oncology franchises mature.

Andrew Dickinson added shares on June 11 and June 16; Johanna Mercier also bought on June 16, contributing to a six-month aggregate of 283,785 net insider shares purchased. The insider buy-to-sell ratio is 53% buy versus 30% sell, the highest on this screen.

⬡ The FDA approved a key milestone within the oncology pipeline, a development flagged by news coverage as a potential next growth driver while the company prepares for the August 6 earnings call where management will guide on commercial uptake.

5. GSK plc (GSK)

P/E: 13.3 | Earnings yield: 7.5% | 52w drawdown: -17.3%

ROIC reaches 19.9% with gross margin at 72.4%, driving a 4.7% FCF yield and a 3.5% dividend while normalized P/E of 14.3 sits just below the current 13.3 multiple. Revenue expanded 4.1% year-over-year, accelerating the pace from prior quarters.

⬡ GSK and partner Spero Therapeutics secured FDA approval for Utebzi, the first oral carbapenem antibiotic for complicated urinary tract infections, opening a new commercial category within the infectious disease portfolio. The drug addresses carbapenem-resistant pathogens, a rising clinical need with limited treatment options.

Insider activity over the past six months totaled zero net share changes despite five recorded transactions, suggesting management is rotating rather than adding to positions.

Only Pro and Free Trial readers get meta-analysis of the top 5 ranked Value stocks.

6. KLA Corporation (KLAC)

P/E: 7.3 | Earnings yield: 13.7% | 52w drawdown: -87.5%

ROIC of 66.5% stands as the highest figure on the screen, pairing with an 11.1% FCF yield and 60.9% gross margin as revenue surged 23.9% year-over-year. The normalized ten-year P/E of 101 reflects prior-cycle peak valuations; the current 7.3 multiple implies a severe dislocation.

CEO Richard P. Wallace sold a small tranche on June 11, part of a six-month net reduction of 7,602 shares, but the modest size suggests programmatic selling rather than thesis abandonment.

The 87.5% drawdown from the 52-week high is the largest on this screen, and the analyst target of $1,855 implies a 619% gain that assumes a full return to semiconductor capital equipment peak multiples—a scenario that historically takes years to unfold.

7. Newmont Corporation (NEM)

P/E: 13.0 | Earnings yield: 7.7% | 52w drawdown: -25.6%

ROIC of 29.9% pairs with a 6.8% FCF yield and 53.2% gross margin while revenue climbed 21.3% year-over-year, marking the fastest top-line expansion among the mining names. Debt-to-equity of 0.16 provides balance-sheet flexibility for project development and M&A optionality.

British Columbia approved Newmont's Red Chris Block Cave project, a Tier 1 asset expected to extend mine life and lower all-in sustaining costs. Insiders added 16,605 net shares over the past six months, with CFO Natascha Viljoen and COO Peter Toth both buying in early June.

Analyst consensus targets $142.82, implying 42.3% upside, yet gold equities have historically required sustained bullion strength above $2,400/oz to re-rate meaningfully, a threshold the metal has tested but not held in recent sessions.

8. Regeneron Pharmaceuticals, Inc. (REGN)

P/E: 14.6 | Earnings yield: 6.8% | 52w drawdown: -27.1%

Gross margin of 85.4% leads the pharma cohort, driving a 6.1% FCF yield and supporting a 6.3% shareholder yield through dividends and buybacks. ROIC of 16.5% and debt-to-equity of 0.09 provide flexibility to fund pipeline expansion while the normalized P/E of 15.7 sits just above the current 14.6 multiple.

Insiders purchased 403,632 net shares over the past six months, the second-largest aggregate on the screen, with a buy-to-sell ratio of 24.6% buy versus 0.3% sell. The dollar commitment signals conviction in the ophthalmology and immunology franchises as biosimilar pressures subside.

Revenue growth slowed to 1.0% year-over-year, the lowest pace among the pharma names, as Eylea biosimilar competition weighs on the top line while next-generation product uptake accelerates from a smaller base.

What to Watch

• Gilead earnings on August 6 will provide the first commercial update on the FDA-approved oncology milestone and guide on HIV franchise momentum heading into the second half.

• Regeneron earnings on July 30 offer visibility into Eylea HD uptake and the biosimilar impact trajectory, critical for assessing whether revenue stabilization is achievable in 2026.

• EQT earnings on July 21 will quantify realized pricing on the 60% volume surge and clarify whether operating leverage can sustain the 9.2% ROIC profile through the next quarter.

• GSK earnings on July 28 will break out Utebzi launch metrics and signal whether the first-in-class antibiotic can materially offset Shingrix deceleration.

Go Deeper

The value screener isolates names trading below ten-year normalized multiples while generating high earnings yields and positive free cash flow.

Check out the full screener →

Pro-only analytics

Named tickers from this article open in the app with Pro or an active trial.

Stock Pixie Pro

See the full Buy the Dip screen — every pick, every metric, every day.

The app shows up to 10 rows on Free; the top 5 by Pixie rank keep ticker, name, and recent close private. Posts may name the top 5 for context. Pro and trial show every row on the screener, full identifiers, and the rest of Pro.

Start your free trial →

About the Stock Pixie Score

The Stock Pixie Score is a 0–10 composite that measures how well a stock matches the criteria for that screen. Scores reflect the strength of quantitative signals across valuation, quality, and trend factors weighted for the specific screener. A higher score means stronger alignment; above 8 indicates the algorithm finds the setup compelling across most of the metrics it tracks. It is a filter, not a forecast.

The Fine Print

Stock Pixie is not a registered investment adviser and does not offer financial advice. It is a stock screening platform that scores and ranks stocks using quantitative signals. You are responsible for your own research and investment decisions. Past performance does not guarantee future results.